Back to top

A Phase I study that evaluated whether a gel containing dapivirine is safe for use in the rectum. The study, which enrolled 28 HIV-negative cisgender and transgender men and women at sites in Thailand and the U.S., will help determine whether further testing on the safety and acceptability of dapivirine gel as a potential rectal microbicide can be conducted in a larger population. Results are anticipated in mid-2020.


MTN-026 Backgrounder



MTN-026 Q&A



See Also

MTN-026 Protocol


MTN-026 Study Page


Rectal Microbicides - Fact Sheet